AbbVie (ABBV) Stock Analysis

September 7, 2026

This is a peer-relative look at AbbVie (ABBV): its performance, risk, profitability, growth, financial strength, dividend, and valuation are each measured against its Pharmaceuticals, Biotechnology & Life Sciences peers, so every number reads in context rather than in isolation.

Company Profile

Company profile fields for AbbVie (ABBV)
Profile Item	ABBV
Name	AbbVie Inc.
Country/Region	United States
GICS Sector	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology
GICS Sub-Industry	Biotechnology
Market Capitalization	453.19 billion USD
Currency	USD
Exchange	NYSE
Listing Date	January 2, 2013
Security Type	Common Stock

Price Performance

Cumulative Growth

ABBV

GSPC

AbbVie (ABBV) vs. S&P 500 (GSPC): Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for AbbVie (ABBV) and S&P 500 (GSPC). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for AbbVie (ABBV) and S&P 500 (GSPC). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

AbbVie (ABBV) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: ABBV	Industry group median
Total Return (1Y)	24.14%	48.26%
Total Return (3Y, Annualized)	24.28%	12.46%
Total Return (5Y, Annualized)	22.52%	-4.88%

Risk Profile

Drawdown History

ABBV

GSPC

AbbVie (ABBV) vs. S&P 500 (GSPC): Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for AbbVie (ABBV) and S&P 500 (GSPC). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

AbbVie (ABBV) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: ABBV	Industry group median
Volatility (1Y, Annualized)	26.50%	67.21%
Beta (5Y)	0.24	0.93
Max Drawdown (5Y)	-21.92%	-82.64%

Risk-Adjusted Performance

Risk-Return Positioning

Each dot is a stock plotted by 1-year volatility (risk) and 1-year return. ABBV is highlighted; the dashed line is the Capital Allocation Line from the risk-free rate through the industry median — dots above it are stronger on a risk-adjusted basis.

Risk-Adjusted Metrics

AbbVie (ABBV) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: ABBV	Industry group median
Sharpe Ratio (1Y)	0.76	0.78
Sortino Ratio (1Y)	1.19	1.30

Profitability

ROE (TTM)

No usable ROE is available for AbbVie (ABBV) this period, so the shareholder-equity return read is skipped.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

Group distribution

Max: 102.29%
Q3: 3.16%
Median: -32.34%
Q1: -64.79%
Min: -157.61%
ABBV: --

Largest peers

LLY: 102.29%
AMGN: 91.47%
NVS: 30.35%
JNJ: 25.74%
AZN: 21.97%
MRK: 6.96%
ABBV: --

AbbVie (ABBV) doesn’t report ROE this period; the box shows the Pharmaceuticals, Biotechnology & Life Sciences group’s distribution and the dots its largest members.

Net Margin (TTM)

AbbVie (ABBV) keeps 9.80% of revenue as net profit, putting net margin in the upper peer quartile. After operating costs, interest, and taxes, more of each sales dollar reaches shareholders than it does at most industry peers.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.80%

Group distribution

Max: 12.02%
ABBV: 9.80%
Q3: 2.44%
Median: 0.00%
Q1: -4.89%
Min: -13.51%

Largest peers

LLY: 33.53%
AMGN: 22.95%
NVS: 22.50%
JNJ: 21.48%
AZN: 17.02%
ABBV: 9.80%
MRK: 4.77%

Where AbbVie (ABBV) stands on net margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Operating Margin (TTM)

AbbVie (ABBV) turns 40.04% of revenue into operating profit, putting operating margin in the upper peer quartile. Before financing and taxes enter the picture, the day-to-day business keeps more of each sales dollar than most industry peers.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

40.04%

Group distribution

Max: 76.04%
ABBV: 40.04%
Q3: 10.45%
Median: 0.00%
Q1: -120.32%
Min: -308.66%

Largest peers

LLY: 54.22%
ABBV: 40.04%
AMGN: 35.55%
NVS: 34.62%
JNJ: 29.19%
AZN: 23.46%
MRK: -0.24%

Where AbbVie (ABBV) stands on operating margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Profitability Metrics

AbbVie (ABBV) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: ABBV	Industry group median
ROE (TTM)	--	-32.34%
ROA (TTM)	10.51%	-14.69%
Net Margin (TTM)	9.80%	0.00%
Operating Margin (TTM)	40.04%	0.00%
Gross Margin (TTM)	72.79%	33.96%

Growth

Revenue Growth

AbbVie (ABBV) grew revenue 8.57%, roughly around the peer group's normal range. Top-line momentum looks broadly typical for the industry.

AbbVie (ABBV): Revenue Growth across different time periods, set against Pharmaceuticals, Biotechnology & Life Sciences industry-group medians.

EPS Growth

AbbVie (ABBV) grew earnings per share -1.26%, roughly around the peer group's normal range. Bottom-line momentum looks broadly typical for the industry.

AbbVie (ABBV): EPS Growth across different time periods, set against Pharmaceuticals, Biotechnology & Life Sciences industry-group medians.

Growth Metrics

AbbVie (ABBV) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: ABBV	Industry group median
Revenue Growth (YoY)	8.57%	10.61%
Revenue Growth (3Y CAGR)	1.75%	10.96%
EPS Growth (YoY)	-1.26%	3.16%
EPS Growth (3Y CAGR)	-29.13%	3.62%

Financial Strength

Current Ratio (MRQ)

AbbVie (ABBV) has current ratio of 0.81, in the tighter-liquidity quartile for its industry. The short-term cushion is thinner than most peers carry, even if the absolute comfort level still depends on the business model.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.81

Group distribution

Max: 26.10
Q3: 12.34
Median: 5.72
Q1: 2.80
ABBV: 0.81
Min: 0.10

Largest peers

AMGN: 1.37
LLY: 1.36
MRK: 1.32
JNJ: 1.09
AZN: 0.89
NVS: 0.86
ABBV: 0.81

Where AbbVie (ABBV) stands on current ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Debt / Equity (MRQ)

No usable debt-to-equity ratio is available for AbbVie (ABBV) this period, so the balance-sheet leverage read is skipped.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

Group distribution

Max: 1.56
Q3: 0.64
Median: 0.14
Q1: 0.02
Min: 0.00
ABBV: --

Largest peers

AMGN: 4.90
LLY: 1.62
MRK: 1.28
NVS: 1.17
AZN: 0.64
JNJ: 0.58
ABBV: --

AbbVie (ABBV) doesn’t report debt-to-equity ratio this period; the box shows the Pharmaceuticals, Biotechnology & Life Sciences group’s distribution and the dots its largest members.

Financial Strength Metrics

AbbVie (ABBV) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: ABBV	Industry group median
Current Ratio (MRQ)	0.81	5.72
Debt / Equity (MRQ)	--	0.14
Net Debt / EBITDA	2.09	1.15

Dividends

Dividend Yield (TTM)

AbbVie (ABBV) has dividend yield of 2.62%, above the entire industry range. That headline income is large, but yields this far above peers often come from a falling share price or an at-risk payout, so dividend safety matters more than the percentage itself.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.62%

Group distribution

ABBV: 2.62%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Largest peers

NVS: 2.86%
ABBV: 2.62%
AMGN: 2.21%
MRK: 2.18%
AZN: 1.96%
JNJ: 1.88%
LLY: 0.56%

Where AbbVie (ABBV) stands on dividend yield within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Payout Ratio (TTM)

AbbVie (ABBV) has payout ratio of 190.40%, meaning dividends exceeded current-period earnings. The gap would need to be covered by cash, retained earnings, financing, or other sources, so earnings alone do not support the payout.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

190.40%

Group distribution

ABBV: 190.40%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Largest peers

MRK: 268.80%
ABBV: 190.40%
NVS: 71.60%
AMGN: 60.87%
JNJ: 60.79%
AZN: 47.41%
LLY: 21.69%

Where AbbVie (ABBV) stands on payout ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Metrics

AbbVie (ABBV) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: ABBV	Industry group median
Dividend Yield (TTM)	2.62%	0.00%
Dividend Payout Ratio (TTM)	190.40%	0.00%

Valuation

P/E Ratio (TTM)

AbbVie (ABBV) trades at P/E ratio of 72.45, in the richer earnings-multiple quartile for its industry. That premium needs support from growth, durable earnings, or stronger business quality.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

72.45

Group distribution

Max: 83.73
ABBV: 72.45
Q3: 44.68
Median: 28.50
Q1: 15.51
Min: 0.14

Largest peers

MRK: 120.26
ABBV: 72.45
LLY: 38.61
JNJ: 31.97
AMGN: 27.17
AZN: 24.32
NVS: 24.17

Where AbbVie (ABBV) stands on P/E ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

P/S Ratio (TTM)

AbbVie (ABBV) trades at 7.04 on P/S ratio, roughly in the peer group’s normal range. The market is not making a strong cheap-or-rich statement about its revenue base.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.04

Group distribution

Max: 65.27
Q3: 29.50
Median: 7.31
ABBV: 7.04
Q1: 3.49
Min: 0.01

Largest peers

LLY: 12.86
ABBV: 7.04
JNJ: 6.77
AMGN: 6.21
MRK: 5.57
NVS: 5.36
AZN: 4.11

Where AbbVie (ABBV) stands on P/S ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

P/B Ratio (MRQ)

AbbVie (ABBV) has negative P/B ratio of -76.35, which means reported book equity is negative. Price-to-book breaks down in this situation and should not be used as a valuation signal.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

-76.35

Group distribution

Max: 15.46
Q3: 7.32
Median: 4.02
Q1: 1.90
Min: -5.81
ABBV: -76.35

Largest peers

LLY: 30.24
AMGN: 20.22
MRK: 8.85
JNJ: 7.80
NVS: 7.32
AZN: 5.02
ABBV: -76.35

Where AbbVie (ABBV) stands on P/B ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Valuation Metrics

AbbVie (ABBV) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: ABBV	Industry group median
P/E Ratio (TTM)	72.45	28.50
P/S Ratio (TTM)	7.04	7.31
P/B Ratio (MRQ)	-76.35	4.02
Free Cash Flow Yield (TTM)	3.72%	-1.84%